Reply by Authors

Affiliations

¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Urology, University of Illinois at Chicago, Chicago, Illinois.
³ Division of Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida.
⁴ Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁶ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
⁷ Department of Urology and Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Comment

Mounsif Azizi et al. J Urol. 2020 Jun.

. 2020 Jun;203(6):1155.

doi: 10.1097/JU.0000000000000746.03. Epub 2020 Mar 16.

¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Urology, University of Illinois at Chicago, Chicago, Illinois.
³ Division of Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida.
⁴ Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁶ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
⁷ Department of Urology and Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

No abstract available

Comment on

Editorial Comment.
McIntosh AG, Tu SM. McIntosh AG, et al. J Urol. 2020 Jun;203(6):1154. doi: 10.1097/JU.0000000000000746.01. Epub 2020 Mar 16. J Urol. 2020. PMID: 32176596 No abstract available.
Editorial Comment.
Nicolai N. Nicolai N. J Urol. 2020 Jun;203(6):1154-1155. doi: 10.1097/JU.0000000000000746.02. Epub 2020 Mar 16. J Urol. 2020. PMID: 32176597 No abstract available.